Showing papers on "Female Sexual Arousal Disorder published in 2013"
TL;DR: It is hypothesized that a single dose of 5-hydroxytryptamine receptor agonist (5-HT(1A)ra) will reduce the sexual-stimulation-induced PFC-mediated sexual inhibition during a short period after administration, and treatment with T+5- HT(1 a)ra will be more effective, in particular in women exhibiting sexual inhibition.
54 citations
TL;DR: Definitions of the different types of FSAD are given, their aetiology, prevalence and comorbidity with somatic and psychological disorders, as well as to discuss different medical and psychological assessment and treatment modalities are given.
50 citations
TL;DR: Cluster analyses supported the distinction between desire and genital arousal difficulties, and suggest that different groups with distinct clusters of symptoms may exist, two of which are consistent with the DSM-5 criteria.
Abstract: A controversial proposal to collapse sexual disorders of desire and arousal is forthcoming in the Diagnostic and Statistical Manual of Mental Disorders (5th ed.) (DSM-5). Yet, no study has attempted to empirically distinguish these disorders by using explicit criteria to recruit and compare distinct groups of low desire and arousal sufferers. The goal of the current study was to test the feasibility of finding medically healthy men and women meeting clearly operationalized DSM-IV-TR criteria for disorders of desire and/or arousal and compare them to matched controls. To assess operational criteria, participants completed a comprehensive telephone screening interview assessing DSM-IV-TR and DSM-5 criteria, as well as standardized self-report measures of sexual functioning. The use of operationalized DSM-IV-TR criteria to recruit participants led to the exclusion of over 75 % of those reporting sexual difficulties, with the primary reason for exclusion being failure to meet at least one central diagnostic criterion. The application of the DSM-5 criteria was even more restrictive and led to the exclusion of all but four men and one woman using the original four-symptom criteria, and four men and five women using the revised three-symptom criteria. Cluster analyses supported the distinction between desire and genital arousal difficulties, and suggest that different groups with distinct clusters of symptoms may exist, two of which are consistent with the DSM-5 criteria. Overall, results highlight the need for revisions to the diagnostic criteria, which, as they stand, do not capture the full range of many people’s sexual difficulties.
30 citations
TL;DR: Although improvements were seen with CP-866,087 in the key efficacy end points, there was no clinical treatment benefit over placebo and the exit interview analysis suggested that being part of the study and taking positive action to search for a solution to the women's sexual disorder may have been a significant factor in the behavioral changes that were seen.
10 citations
25 Mar 2013
TL;DR: It is proposed that the sole use of sildenafil may not be an effective treatment for FSAD, because women’s sexual problems may become worse and their self-confidence may be negatively affected if improper treatment approach is nominated.
Abstract: Female sexual arousal disorder (FSAD) is one of the subcategories of female sexual dysfunction (FSD). During recent years, many different chemical and herbal medicines have been introduced to the market by pharmaceutical companies targeting women who suffer sexual dysfunction. Notwithstanding, the majority of these medications failed to demonstrate their efficacy in experimental studies. Regarding the fact that men and women are increasingly becoming similar in terms of life style, familial and social responsibilities, etc, treating female sexual problems by the use of sildenafil citrate (Viagra) has become of interest to many physicians and professionals. This drug is a phosphodiesterase type 5 inhibitor and is commonly used for the treatment of erectile dysfunction. Evaluation of the effect of sildenafil on FSAD has yielded controversial results and still there is no unanimity on this issue. The focus of this review article is on the efficacy of sildenafil as a treatment for FSAD. Regarding the fact that women’s sexual dysfunction is a biopsychosocial disorder with a multifaceted etiology, it is proposed that the sole use of sildenafil may not be an effective treatment for FSAD. All aspects of female sexuality should be taken into account during evaluation of female sexual function and when therapeutic approaches for FSAD are introduced. As a matter of fact, women’s sexual problems may become worse and their self-confidence may be negatively affected if improper treatment approach is nominated. Keywords-Female Sexual Arousal Disorder; Female Sexual Dysfunction; Sildenafil
1 citations
Patent•
18 Feb 2013
TL;DR: In this paper, a method for typing a subject suffering from a Hypoactive Sexual Desire Disorder (HSDD) and/or Female Sexual Arousal Disorder (FSAD) was described.
Abstract: The present invention relates to a method of typing a subject suffering from a Hypoactive Sexual Desire Disorder (HSDD) and/or Female Sexual Arousal Disorder (FSAD). In addition, the invention relates to a method of treating a subject suffering from a Hypoactive Sexual Desire Disorder, the method comprising typing a subject suffering from a HSDD and/or FSAD according to the methods the invention, and treating a subject that was typed as experiencing sexual inhibition with testosterone or functional analogue thereof and a 5HT1a receptor agonist.
1 citations
Patent•
19 Jul 2013
TL;DR: The Intravaginal DHEA is used for the treatment of at least one condition selected from the group consisting of female hypoactive sexual desire disorder, female sexual arousal disorders, female orgasm disorder and female sexual interest arousal disorder in a woman who either suffers from symptoms of vulvo-vaginal atrophy and/or is not suffering from moderate to severe dyspareunia.
Abstract: Intravaginal DHEA is used for the treatment of at least one condition selected from the group consisting of female hypoactive sexual desire disorder, female sexual arousal disorder, female orgasm disorder and female sexual interest arousal disorder in a woman who either (1) is not suffering from symptoms of vulvo-vaginal atrophy and/or (2) is not suffering from moderate to severe dyspareunia.
Patent•
19 Jul 2013
TL;DR: The Intravaginal DHEA is used for the treatment of at least one condition selected from the group consisting of female hypoactive sexual desire disorder, female sexual arousal disorders, female orgasm disorder and female sexual interest arousal disorder in a woman who either suffers from symptoms of vulvo-vaginal atrophy and/or is not suffering from moderate to severe dyspareunia as discussed by the authors.
Abstract: Intravaginal DHEA is used for the treatment of at least one condition selected from the group consisting of female hypoactive sexual desire disorder, female sexual arousal disorder, female orgasm disorder and female sexual interest arousal disorder in a woman who either (1) is not suffering from symptoms of vulvo-vaginal atrophy and/or (2) is not suffering from moderate to severe dyspareunia.
Patent•
05 Dec 2013
TL;DR: In this paper, a combination of testosterone or its analogue and a compound that can at least partially inhibit smooth muscle constriction was used to treat female sexual dysfunction, such as female sexual arousal disorder (FSAD) or female sexual desire disorder.
Abstract: PROBLEM TO BE SOLVED: To provide an effective therapy for female sexual dysfunction (such as female sexual arousal disorder (FSAD) or female sexual desire disorder (FSDD)).SOLUTION: A therapy includes use of a combination of testosterone or its analogue and tadalafil. Preferably, the therapy includes use of a combination of testosterone or its analogue and a compound that can at least partially inhibit smooth muscle constriction, for example, a compound capable of at least partially inhibiting an adrenergic tone. An example of the above compound is prazosin, thymoxamine (moxisylyte), NMI-870, HMP12, or phentolamine.
Patent•
16 Jul 2013
TL;DR: The Intravaginal DHEA is used for the treatment of at least one condition selected from the group consisting of female hypoactive sexual desire disorder, female sexual arousal disorders, female orgasm disorder and female sexual interest arousal disorder in a woman who either suffers from symptoms of vulvo-vaginal atrophy and/or is not suffering from moderate to severe dyspareunia as mentioned in this paper.
Abstract: Intravaginal DHEA is used for the treatment of at least one condition selected from the group consisting of female hypoactive sexual desire disorder, female sexual arousal disorder, female orgasm disorder and female sexual interest arousal disorder in a woman who either (1) is not suffering from symptoms of vulvo-vaginal atrophy and/or (2) is not suffering from moderate to severe dyspareunia.